<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306591</url>
  </required_header>
  <id_info>
    <org_study_id>Bevacizumab for nAMD</org_study_id>
    <nct_id>NCT01306591</nct_id>
  </id_info>
  <brief_title>Bevacizumab for Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>Randomized Multi-center Clinical Studyï¼šBevacizumab for Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related macular degeneration (AMD) is one of primary blinding eye disease among people
      over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular
      Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available
      low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized
      trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the
      effective therapeutic approach that the majority of patients in China can bear establishing a
      suitable treatment for China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EDTRS visual acuity score</measure>
    <time_frame>0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week</time_frame>
    <description>EDTRS visual acuity score is assessed at each timepoint for every group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>macular thickness in OCT</measure>
    <time_frame>0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week</time_frame>
    <description>macular thickness is assessed at each timepoint for every group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Bevacizumab 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab 1</intervention_name>
    <description>Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks</description>
    <arm_group_label>Bevacizumab 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week</description>
    <arm_group_label>Bevacizumab 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of neovascular Age-related macular degeneration

          -  Signed informed consent

        Exclusion Criteria:

          -  No other ocular fundus diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoxin Li, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiaoxin Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>March 1, 2011</last_update_submitted>
  <last_update_submitted_qc>March 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Peking University People's Hospital</name_title>
    <organization>Peking University People's Hospital</organization>
  </responsible_party>
  <keyword>neovascular age-related macular degeneration</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Multicenter Randomized Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

